ReviewMolecules (Basel, Switzerland)2024
Inhibitors of Cyclophilin A: Current and Anticipated Pharmaceutical Agents for Inflammatory Diseases and Cancers.
Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 9 citations in OpenAlex.
- Predictive Value of Combined Serum NOX4, Gal-13, and Cyclophilin A for Prognosis in Severe Pneumonia.International journal of general medicine · 2026Article
- All-atom molecular dynamics simulation of Cyclophilin A in complex with Sanglifehrin A.PloS one · 2026Article
- High Blood Levels of Cyclophilin A Increased Susceptibility to Ulcerative Colitis in a Transgenic Mouse Model.International journal of molecular sciences · 2025Article
- The role of eCyPA as an inflammatory biomarker for predicting 28-day mortality in ARDS patients.Respiratory research · 2025Article
- Cyclophilins as key players in protozoan parasite infections.Parasites & vectors · 2025Review
- Democratized Discovery of Microsclerodermin F as an Immunophilin Ligand.Marine drugs · 2025Article
- Cyclosporin A alleviates influenza A (H1N1) virus-induced chronic pulmonary inflammation through decreasing IFN-γ-producing T lymphocytes.Virology journal · 2025Article
- Drugging mutant KRAS by disrupting binding to effectors and GTP.Nature cancer · 2025Article
- "Undruggable KRAS": druggable after all.Genes & development · 2025Review
- Tick saliva protein fraction inhibits breast cancer by decreasing cell viability and promoting apoptosis in vitro.PloS one · 2025Article
- Differential Expression of Neurodegeneration-Related Genes in SH-SY5Y Neuroblastoma Cells Under the Influence of Cyclophilin A: Could the Enzyme be a Likely Trigger and Therapeutic Target for Alzheimer's Disease?Neurochemical research · 2024Article
- Brain cell-released Cyclophilin A induces neuroinflammation and exacerbates blood-brain barrier injury in acute ischemic stroke.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cyclophilin A, a widely prevalent cellular protein, exhibits peptidyl-prolyl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.